ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 14.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,498 shares of the specialty pharmaceutical company’s stock after buying an additional 1,211 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in ANI Pharmaceuticals were worth $605,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Texas Permanent School Fund Corp lifted its stake in ANI Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after buying an additional 172 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in shares of ANI Pharmaceuticals by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after acquiring an additional 200 shares in the last quarter. Arizona State Retirement System boosted its stake in ANI Pharmaceuticals by 4.7% in the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 211 shares during the period. Simplicity Wealth LLC grew its position in ANI Pharmaceuticals by 3.5% during the 2nd quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 227 shares in the last quarter. Finally, California State Teachers Retirement System raised its stake in ANI Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after purchasing an additional 233 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $58.60 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. The firm has a market cap of $1.23 billion, a PE ratio of 36.63 and a beta of 0.71. The firm’s 50 day moving average price is $59.41 and its 200 day moving average price is $62.55. ANI Pharmaceuticals, Inc. has a twelve month low of $48.20 and a twelve month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The firm had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. ANI Pharmaceuticals’s revenue for the quarter was up 18.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.06 earnings per share. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ANIP. Truist Financial reiterated a “hold” rating and set a $60.00 price target (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, Raymond James increased their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.